Systemic sclerosis: comparison of efficacy of oral cyclophosphamide and azathioprine on skin score and pulmonary involvement—a retrospective study

Rheumatology International

Volumn 34, Issue 12, 2014, Pages 1691-1699

  Poormoghim, Hadi ^a   Rezaei, Nader ^b   Sheidaie, Zeinab ^b   Almasi, Ali Reza ^b   Moradi Lakeh, Maziar ^b   Almasi, Simin ^a   Andalib, Elham ^c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Azathioprine; Cyclophosphamide; Interstitial lung disease (ILD); Systemic sclerosis (SSc)

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; PREDNISOLONE;

ADULT; AGED; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECTS; FEMALE; HUMAN; LUNG; LUNG DIFFUSION CAPACITY; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOLOGY; PATHOPHYSIOLOGY; REMISSION; RETROSPECTIVE STUDY; SCLERODERMA, SYSTEMIC; SKIN; SKIN DISEASES; TIME; TREATMENT OUTCOME; VITAL CAPACITY; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; AGED; AZATHIOPRINE; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; PREDNISOLONE; PULMONARY DIFFUSING CAPACITY; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC; SKIN; SKIN DISEASES; TIME FACTORS; TREATMENT OUTCOME; VITAL CAPACITY; YOUNG ADULT;

EID: 84939874515     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-014-3026-y     Document Type: Article

References (24)

1. Silver RM (1991) Clinical aspect of systemic sclerosis. Ann Rheu Dis 50:854–861
2. Silver RM, Warrick JH, Kinsella MB, Staudt LS, Baumann MH, Strange C (1993) Cyclophosphamide and low dose prednisolone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol 20:838–844
3. Davas EM, Peppas C, Maragou M, Alvanou E, Hondros D, Dantis PC (1999) Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma. Clin Rheumatol 18(6):455–461
4. Akesson A, Scheja A, Lundin A, Wollheim FA (1994) Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. Arthritis Rheum 37(5):729–735
5. White B, Moore WC, Wigley FM, Xiao HQ, Wise RA (2000) Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 132:947–954
6. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, Silver R et al (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354:2655–2666
7. Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS et al (2006) A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 54:3962–3970
8. Raghu G, Depaso WJ, Cain K, Hammar SP, Wetzel CE, Dreis DF, Winterbauer RH et al (1991) Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective, double-blind randomized, placebo-controlled clinical trial. Am Rev Respir Dis 144:291–296
9. Winterbauer RH, Hammar SP, Hallman KO, Hays JE, Pardee NE, Morgan EH et al (1978) Diffuse interstitial pneumonitis: clinicopathologic correlations in 20 patients treated with prednisone/azathioprine. Am J Med 65:661–672
10. Dheda K, Lallo UG, Cassim B, Mody GM (2004) Experience with azathioprine in systemic sclerosis associated with interstitial lung disease. Clin Rheumatol 23:306–309
11. Nadashkevich O, Davis P, Fritzler M, Kovalenko W (2006) A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin Rheumatol 25:205–212
12. Subcommittee for Scleroderma Criteria of American Rheumatism Association Diagnostic, Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (Scleroderma). Arthritis Rheum 23:581–590
13. Au K, Khanna D, Clements PJ, Furst DE, Tashkin DP (2010) Current concepts in disease modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials. Curr Rheumatol Rep 11(2):111–119
14. Miller MR, Crapo R, Hankinson J, Brusasco V, Burgos F, Casaburi R et al (2005) General considerations for lung function testing. Eur Respir J 26:153–161
15. Simeon-Anzar CP, Fonollosa-Pla V, Tolosa-Vilella C, Selva-oCallaghan A, Solans-Laque R, Palliza E (2008) Intravenous cyclophosphamide pulse therapy in the treatment of systemic sclerosis-related interstitial lung disease: a long term study. Open Respir Med J 2:39–45
16. Wells AU, Hansell DM, Corrin B, Harrison NK, Goldstraw P, Black CM, du Bois RM (1992) High resolution computed tomography as a predictor of lung histology in systemic sclerosis. Thorax 47:738–742
17. Poormoghim H, Moghadam AS, Moradi-Lakeh M, Jafarzadeh M, Asadifar B, Ghelman M et al (2013) Systemic sclerosis: demographic, clinical and serological features in 100 Iranian patients. Rheumatol Int 33(8):1943–1950
18. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, Rowell N, Wollheim F (1988) Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol 15:202–205
19. Bérezné A, Valeyre D, Ranque B, Guillevin L, Mouthon L (2007) Interstitial lung disease associated with systemic sclerosis. What is the evidence for efficacy of cyclophosphamide? Ann N Y Acad Sci 1110:271–284
20. Steen VD, Medsger TA Jr, Rodnan GP (1982) D-penicillamine therapy in progressive systemic sclerosis (sleroderma). Ann Intern Med 97:652–659
21. Baltus JA, Boersma JW, Hartman AP, Vandenbroucke JP (1983) The occurrence of malignancies in patients with rheumatoid arthritis treated with cyclophosphamide: a controlled retrospective follow-up. Ann Rheum Dis 42:368–373
22. Bérezné A, Ranque B, Valeyre D, Brauner M, Allanore Y, Launay D (2008) Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study. J Rheumatol 35(6):1064–1072
23. Amjadi S, Maranian P, Furst DE, Clements PJ, Wong WK, Postlethwaite AE et al (2009) Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials. Arthritis Rheum 60(8):2490–2498
24. Scheja A, Hesselstrand R, Wildt M, Akesson A (2007) Relapse of skin thickening after discontinuation or decrease of azathioprine therapy in a patient with diffuse cutaneous systemic sclerosis. Rheumatology 46:1862–1863